The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis

DNA and Cell Biology

Volumn 27, Issue 8, 2008, Pages 405-413

  Li, Min ^a   Yu, Da Hai ^a   Cai, Hong ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DNA VACCINE; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 12; LYSYLLEUCYLLYSYLLEUCYLLEUCYLLEUCYLLEUCYLLEUCYLLYSYLLEUCYLLYSYLAMIDE CARBOXYLIC ACID; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; LYSYL LEUCYL LYSYL LEUCYL LEUCYL LEUCYL LEUCYL LEUCYL LYSYL LEUCYL LYSINE; LYSYL-LEUCYL-LYSYL-LEUCYL-LEUCYL-LEUCYL-LEUCYL-LEUCYL-LYSYL-LEUCYL-LYSINE; OLIGOPEPTIDE; RECOMBINANT VACCINE; SUBUNIT VACCINE;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUBERCULOSIS; ANIMAL; DISEASE MODEL; FLOW CYTOMETRY; GENE VECTOR; IMMUNITY; IMMUNOLOGY; PLASMID;

MUS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GENETIC VECTORS; IMMUNITY; MICE; MYCOBACTERIUM TUBERCULOSIS; OLIGOPEPTIDES; PLASMIDS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 51649131501     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2007.0693     Document Type: Article

References (34)

1. Agger, E.M., Rosenkrands, I., Olsen, A.W., Hatch, G., Williams, A., Kritsch, C., Lingnau, K., Von Gabain, A., Andersen, C.S., Korsholm, K.S., and Andersen, P. (2006). Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 24, 5452-5460.
2. Alvarez-Bravo, J., Kurata, S., and Natori, S. (1994). Novel synthetic antimicrobial peptides effective against methicillin-resistant Staphylococcus aureus. Biochem J 302 (Pt 2), 535-538.
3. Anon, W.H.O. (2006). Global Tuberculosis Control, Surveillance, Planning, Financing (WHO, Geneva), pp. 1-242.
4. Boman, H.G. (2000). Innate immunity and the normal microflora. Immunol Rev 173, 5-16.
5. Brandt, L., Feino Cunha, J., Weinreich Olsen, A., Chilima, B., Hirsch, P., Appelberg, R., and Andersen, P. (2002). Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 70, 672-678.
6. Cai, H., Hu, X.D., Yu, D.H., Li, S.X., Tian, X., and Zhu, Y.X. (2005a). Combined DNA vaccine encapsulated in microspheres enhanced protection efficacy against Mycobacterium tuberculosis infection of mice. Vaccine 23, 4167-4174.
7. Cai, H., Tian, X., Hu, X.D., Li, S.X., Yu, D.H., and Zhu, Y.X. (2005b). Combined DNA vaccines formulated either in DDA or in saline protect cattle from Mycobacterium bovis infection. Vaccine 23, 3887-3895.
8. Cai, H., Yu, D.H., Hu, X.D., Li, S.X., and Zhu, Y.X. (2006). A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge. DNA Cell Biol 25, 438-447.
9. Cai, H., Yu, D.H., Tian, X., and Zhu, Y.X. (2005c). Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis. DNA Cell Biol 24, 605-613.
10. Dalpke, A., Frank, J., Peter, M., and Heeg, K. (2006). Activation of toll-like receptor 9 by DNA from different bacterial species. Infect Immun 74, 940-946.
11. Edwards, K.M., Cynamon, M.H., Voladri, R.K., Hager, C.C., Destefano, M.S., Tham, K.T., Lakey, D.L., Bochan, M.R., and Kernodle, D.S. (2001). Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am J Respir Crit Care Med 164, 2213-2219.
12. Fritz, J.H., Brunner, S., Birnstiel, M.L., Buschle, M., Gabain, A., Mattner, F., and Zauner, W. (2004). The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. Vaccine 22, 3274-3284.
13. Geluk, A., van Meijgaarden, K.E., Franken, K.L., Drijfhout, J.W., D'Souza, S., Necker, A., Huygen, K., and Ottenhoff, T.H. (2000). Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans. J Immunol 165, 6463-6471.
14. Ginsberg, A.M. (1998). The tuberculosis epidemic. Scientific challenges and opportunities. Public Health Rep 113, 128-136.
15. Goter-Robinson, C., Derrick, S.C., Yang, A.L., Jeon, B.Y., and Morris, S.L. (2006). Protection against an aerogenic Mycobacterium tuberculosis infection in BCG-immunized and DNA-vaccinated mice is associated with early type I cytokine responses. Vaccine 24, 3522-3529.
16. Grode, L., Seiler, P., Baumann, S., Hess, J., Brinkmann, V., Nasser Eddine, A., Mann, P., Goosmann, C., Bandermann, S., Smith, D., Bancroft, G.J., Reyrat, J.M., van Soolingen, D., Raupach, B., and Kaufmann, S.H. (2005). Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115, 2472-2479.
17. Haile, M., and Kallenius, G. (2005). Recent developments in tuberculosis vaccines. Curr Opin Infect Dis 18, 211-215.
18. Hong, H., and Liu, G.Q. (2004). Scutellarin attenuates oxidative glutamate toxicity in PC12 cells. Planta Med 70, 427-431.
19. Horwitz, M.A., Harth, G., Dillon, B.J., and Maslesa-Galic, S. (2000). Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97, 13853-13858.
20. Huygen, K., Content, J., Denis, O., Montgomery, D.L., Yawman, A.M., Deck, R.R., Dewitt, C.M., Orme, I.M., Baldwin, S., D'Souza, C., Drowart, A., Lozes, E., Vandenbussche, P., van Vooren, J.P., Liu, M.A., and Ulmer, J.B. (1996). Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2, 893-898.
21. Kenney, R.T., and Edelman, R. (2003). Survey of human-use adjuvants. Expert Rev Vaccines 2, 167-188.
22. Kochi, A. (2001). The global tuberculosis situation and the new control strategy of the World Health Organization. 1991. Bull World Health Organ 79, 71-75.
23. Krieg, A.M., Yi, A.K., Matson, S., Waldschmidt, T.J., Bishop, G.A., Teasdale, R., Koretzky, G.A., and Klinman, D.M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
24. Lee, C.G., Choi, S.Y., Park, S.H., Park, K.S., Ryu, S.H., and Sung, Y.C. (2005). The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met as a novel adjuvant for DNA vaccine. Vaccine 23, 4703-4710.
25. Mogues, T., Goodrich, M.E., Ryan, L., Lacourse, R., and North, R.J. (2001). The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 193, 271-280.
26. Morris, S., Kelley, C., Howard, A., Li, Z., and Collins, F. (2000). The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 18, 2155-2163.
27. Nor, N.M., and Musa, M. (2004). Approaches towards the development of a vaccine against tuberculosis: recombinant BCG and DNA vaccine. Tuberculosis (Edinb) 84, 102-109.
28. Roda, J.M., Parihar, R., and Carson, W.E., 3rd. (2005). CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175, 1619-1627.
29. Schellack, C., Prinz, K., Egyed, A., Fritz, J.H., Wittmann, B., Ginzler, M., Swatosch, G., Zauner, W., Kast, C., Akira, S., Von Gabain, A., Buschle, M., and Lingnau, K. (2006). IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24, 5461-5472.
30. Singh, M., and O'Hagan, D. (1999). Advances in vaccine adjuvants. Nat Biotechnol 17, 1075-1081.
31. Skeiky, Y.A., Alderson, M.R., Ovendale, P.J., Guderian, J.A., Brandt, L., Dillon, D.C., Campos-Neto, A., Lobet, Y., Dalemans, W., Orme, I.M., and Reed, S.G. (2004). Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172, 7618-7628.
32. van Drunen Littel-van Den Hurk, S., Babiuk, S.L., and Babiuk, L.A. (2004). Strategies for improved formulation and delivery of DNA vaccines to veterinary target species. Immunol Rev 199, 113-125.
33. van Pinxteren, L.A., Cassidy, J.P., Smedegaard, B.H., Agger, E.M., and Andersen, P. (2000). Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 30, 3689-3698.
34. Weinrich Olsen, A., van Pinxteren, L.A., Meng Okkels, L., Birk Rasmussen, P., and Andersen, P. (2001). Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69, 2773-2778.